This series welcomes healthcare professionals working in the field of HIV. This is the second training of our 4 part series, which was created in collaboration with the MidAtlantic AETC Ending the HIV Epidemic (EHE) Workgroup. This series will allow participants to develop awareness of special populations and how to use trauma-informed practices to enhance HIV care, treatment, and prevention in underserved, stigmatized populations.
For more information on this series, visit: https://www.maaetc.org/p/ehemaaetc
DESCRIPTION:
This program will address the elements of substance use disorder screening, prevention, and treatment in people with HIV.
Speaker:
Jennifer Krebs, LCSW-C
Social Worker & Manager of Substance Use
THRIVE Program | University of Maryland, Midtown
Objectives
Upon completion of this course, participants will be able to:
- Analyze the impact of Substance Use Disorder (SUD) on HIV treatment and care.
- Identify appropriate SUD screening tools, resources, and strategies for various clinical settings.
- Describe the philosophy of harm reduction and its role in both HIV and SUD treatment, care, and prevention.
Acknowledgement:
The MidAtlantic AIDS Education and Training Center (MAAETC) is supported by DHHS, Health Resources and Services Administration (HRSA) as part of a cooperative agreement of $2,917,621 and 0% financed with non-governmental sources. Additional funding provided by the Pennsylvania Department of Health (PA DOH), Bureau of Communicable Diseases, Division of HIV Disease. The views expressed do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. Any trade names for products mentioned are for training and identification purposes only. The contents of this material are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. Funding was made possible in part by U1OHA29295 from the HRSA, HIV/AIDS Bureau and the PA DOH. For more information, please visit HRSA.gov.